Avoid simple carbohydrates, whey protein, BCAAs, and high-dose calcium within 90 minutes of injection
aleniglipron is planning Phase 3 GI tolerability : Aleniglipron has higher nausea rates (65% vs lower for orforglipron) Dose exploration : Aleniglipron explored higher doses (240 mg) with greater efficacy Maintenance data : Orforglipron has ATTAIN-MAINTAIN validation
Phase 2 cagrilintide weight-management trial Review of cagrilintide and related safety data ClinicalTrials.gov cagrilintide study listings Cagrilintide side effects are best understood as a pattern: digestive symptoms are common, while dehydration, allergic symptoms, severe abdominal pain, or glucose problems need timely review
Nausea, vomiting, diarrhea, and constipation topped the list, particularly during dose escalation
Revised April 20, 2024
There is a well-documented relationship between the use of acetaminophen and the reduction of glutathione levels in the body